Disclosures for "Brivaracetam Adjunctive Therapy in Earlier Treatment Lines in Adults with Focal-onset Seizures in Europe and Canada: Interim Results of 12-month Real-world Data From BRITOBA"
-
-
Dr. De Curtis has nothing to disclose.
-
Dr. Kobayashi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Paladin Laboratories. The institution of Dr. Kobayashi has received research support from UCB Canada.
-
Dr. Lema Facal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for angellini. Dr. Lema Facal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ucb.
-
Louis Maillard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Louis Maillard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma.
-
Ms. Rehel has received personal compensation for serving as an employee of UCB.
-
Prof. RHEIMS has nothing to disclose.
-
Anne-Liv Schulz has received personal compensation for serving as an employee of UCB. Anne-Liv Schulz has received stock or an ownership interest from UCB.
-
Iryna Leunikava has nothing to disclose.